Navigation Links
Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
Date:10/10/2007

CALL DATE: Oct. 31, 2007 TIME: 8:30 a.m. Eastern Time HOST: Dr. Candace

Kendle, Chairman and CEO

CINCINNATI, Oct. 10 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast Oct. 31 at 8:30 a.m. Eastern Time to discuss its financial results for the Third Quarter 2007. A question and answer session will follow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=43011. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Nov. 30, 2007. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Nov. 30 by dialing (706) 645-9291 and entering conference ID number 5447273.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Dispelling the top five myths about attending networking events
3. UW engineering career fair sees highest attendance in four years
4. Visions: Broderick says Wisconsin should be in top third in venture capital
5. Third Wave files countersuit vs. Digene in patent case
6. Third Wave reports net loss of $18.9M for 2006
7. Stratagene to pay Third Wave $10.75M in patent case
8. Third Wave responds to Digene patent lawsuit
9. Third Wave seeks approval of Cystic Fibrosis test
10. Third Wave Technologies to raise $14.9M through private debt
11. Venture capital above $6B for third straight quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):